Bispecific dendritic-T cell engager potentiates anti-tumor immunity
Cell · 2024-01 · 187 (2) · 375-389.e18
DOI: 10.1016/j.cell.2023.12.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2024-01. Verfasst von Yuval Shapir Itai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Neoplasms. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most patients do not respond to the treatment or suffer from recurrence. We show that the crosstalk between conventional type I dendritic cells (cDC1) and T cells is essential for an effective aPD-1-mediated anti-tumor response. Accordingly, we developed a bispecific DC-T cell engager (BiCE), a reagent that facilitates physical interactions between PD-1+ T cells and cDC1. BiCE treatment promotes the formation of active dendritic/T cell crosstalk in the tumor and tumor-draining lymph nodes. In vivo, single-cell and physical interacting cell analysis demonstrates the distinct and superior immune reprogramming of the tumors and tumor-draining lymph nodes treated with BiCE as compared to conventional aPD-1 treatment. By bridging immune cells, BiCE potentiates cell circuits and communication pathways needed for effective anti-tumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.
- Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot 7610001, Israel.
- Department of Pathology, Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
- Flow Cytometry Unit, Life Science Core Facility, Weizmann Institute of Science, Rehovot 7610001, Israel.
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: ido.amit@weizmann.ac.il.
- Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: rony.dahan@weizmann.ac.il.
Zitieren
APA
Shapir Itai, Y., Barboy, O., Salomon, R., Bercovich, A., Xie, K., Winter, E., Shami, T., Porat, Z., Erez, N., Tanay, A., Amit, I., & Dahan, R. (2024). Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell, 187(2), 375-389.e18. https://doi.org/10.1016/j.cell.2023.12.011
Vancouver
Shapir Itai Y, Barboy O, Salomon R, Bercovich A, Xie K, Winter E, et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell. 2024;187(2):375-389.e18. doi:10.1016/j.cell.2023.12.011
BibTeX
@article{ShapirItai2024,
author = {Shapir Itai, Yuval and Barboy, Oren and Salomon, Ran and Bercovich, Akhiad and Xie, Ken and Winter, Eitan and Shami, Tamar and Porat, Ziv and Erez, Neta and Tanay, Amos and Amit, Ido and Dahan, Rony},
title = {Bispecific dendritic-T cell engager potentiates anti-tumor immunity},
journal = {Cell},
year = {2024},
volume = {187},
number = {2},
pages = {375--389.e18},
doi = {10.1016/j.cell.2023.12.011}
}
EUVIMED